A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that ...

Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, ...

Long-term exposure to high levels of air pollution can accelerate the progression of both chronic respiratory diseases and pulmonary hypertension.

Columnist Anna Jeter, whose parents also serve as her caregivers, describes their familial arrangement, which works perfectly for them.

The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg ...

Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...

Blood levels of two markers may help predict treatment response and outcomes in pulmonary arterial hypertension patients, per ...

Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...

Keros (KROS) stock plunged 76% Thursday after the company said it has halted two arms of a Phase 2 clinical study of its drug ...

A recent systematic review assessed the psychometric properties of various instruments for measuring QOL in patients with ...

The AIIMS Bhopal has achieved a significant milestone by successfully performing a rare and complex surgery to treat a 27-year-old patient diagnosed with Chronic Thromboembolic Pulmonary Artery ...

After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after a year of muscular performance and its ...